Incyte (INCY) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

INCY Incyte

Watchlist

69.070
+0.650+0.95%

Close Dec 31 16:00 ET

69.670
+0.600+0.87%

Post 20:01 ET

13.31BMarket Cap767.44P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Kevin TraversDec 30, 2024 11:01 ET
Weekly Buzz: So far, Santa is Letting us Down
Kevin TraversDec 27, 2024 16:59 ET
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Kevin TraversDec 27, 2024 10:52 ET
Incyte Corp. Stock Rises Tuesday, Still Underperforms Market
MarketWatchDec 24, 2024 17:22 ET
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Seeking AlphaDec 22, 2024 10:12 ET
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Comments

韭菜变主力

Nov 19, 2024 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

Tynkr Lab

Oct 29, 2024 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14, 2024 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)